EVR 6.7MSFT 0.71DAL 0.73JPM 10.04ATD.TO 0.76MTD 11.16CRWD -28.52
GlaxoSmithKline PLC (GSK)

NYSE:GSK

GlaxoSmithKline PLC (GSK)

51.27
+1.55 (3.12%)
as of Jun 4, 2026, 8:00:00 pm Market Open.
83 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJun 4, 2026, 12:00 am

This summary was created by AI, based on 5 opinions in the last 12 months.

GlaxoSmithKline PLC (GSK) has received positive reviews from various experts, indicating that the stock is progressing well. Each analysis suggests a series of trailing stop recommendations, with significant gains reported for previous top picks, ranging from 17.2% to 80%. Despite challenges in the vaccine sector, where sentiment is currently low, GSK's future prospects seem promising, particularly with ongoing trials that may enhance its drug portfolio. The consensus among experts reflects a cautious but optimistic view, highlighting the importance of disciplined trading strategies to safeguard gains. Overall, while some areas present challenges, the company's trajectory is largely viewed favorably.

consensus icon
Consensus
Positive
valuation icon
Valuation
Fair Value
review icon
Similar
Pfizer, PFE
BUY

GlaxoSmithKline PLC(GSK)

Jun 26, 2001
Good merger. A safe holding.
Photo of Gavin GrahamGavin GrahamUnlock Rating
$55.39

Stock price when the opinion was issued

$51.27

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

GlaxoSmithKline PLC(GSK)

Mar 27, 2001
(Was a top pick on Oct 11 - Down 6%) but still likes it.
Photo of David DriscollDavid DriscollUnlock Rating
$53.15

Stock price when the opinion was issued

$51.27

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

GlaxoSmithKline PLC(GSK)

Mar 27, 2001
Bullet proof portfolio-large caps (40%)
Photo of David DriscollDavid DriscollUnlock Rating
$53.15

Stock price when the opinion was issued

$51.27

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

GlaxoSmithKline PLC(GSK)

Feb 14, 2001
A good merger making them the largest pharmaceutical
Photo of David DriscollDavid DriscollUnlock Rating
$55.31

Stock price when the opinion was issued

$51.27

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
Showing 106 to 109 of 109 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

RY.TO 5.13$270.94
BHP -2.07$88.78
TA.TO -2.08$18
V 7.78$320.18
TOU.TO -0.12$65.42

Today's Top Picks

EVR 6.7$346.79
MSFT 0.71$428.05
DAL 0.73$79.51
JPM 10.04$310.89
ATD.TO 0.76$80.79

Popular Articles

Latest Sell Signals

PRL.TO 0.07$21.2
CNQ.TO -0.14$66.22
SHOP.TO 4.46$161.54
RIO -2.46$105.4
BB.TO 0.3$14.4

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Darren Sissons

Darren Sissons

Campbell Lee & Ross

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Joe Terranova

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica